Serial Number
98139376
Owner
Vanda Pharmaceuticals Inc.Attorney
Jayme M. TorelliFiling Date
Aug 18, 2023
ZIXXIVUS Trademark
Serial Number: 98139376
Trademark Classes
Owner Contact Info
Legal Representation
Correspondence Address
Jayme M. Torelli HOFFMAN WARNICK LLC
6 Tower Place
1st Floor
ALBANY, NY 12203
United States
Trademark Details
Filing Date
August 18, 2023
Registration Date
Not Registered
Published for Opposition
December 19, 2023
Goods & Services
Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention of motion sickness; Pharmaceutical preparations for the prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment and prevention of craving; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of motion sickness; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of Parkinson's Disease Psychosis; Pharmaceutical preparations for the treatment of COVID-19 pneumonia; Pharmaceutical preparations for the treatment of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology